NCT01280188 - A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2012

Conditions

Central Diabetes Insipidus

Interventions

DRUG

Desmopressin Oral Melt

Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.

DRUG

Desmopressin intranasal

Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1

Trial Locations (5)

Unknown

Aichi Medical University, Nagakute, Aichi

Nagoya University Hospital, Nagoya

Osaka Saiseikai Nakatsu Hospital, Osaka

Saitama Medical Center Jichi Medical University, Saitama

Toranomon Hospital, Minato